Jaiswal Siddhartha, Fontanillas Pierre, Flannick Jason, Manning Alisa, Grauman Peter V, Mar Brenton G, Lindsley R Coleman, Mermel Craig H, Burtt Noel, Chavez Alejandro, Higgins John M, Moltchanov Vladislav, Kuo Frank C, Kluk Michael J, Henderson Brian, Kinnunen Leena, Koistinen Heikki A, Ladenvall Claes, Getz Gad, Correa Adolfo, Banahan Benjamin F, Gabriel Stacey, Kathiresan Sekar, Stringham Heather M, McCarthy Mark I, Boehnke Michael, Tuomilehto Jaakko, Haiman Christopher, Groop Leif, Atzmon Gil, Wilson James G, Neuberg Donna, Altshuler David, Ebert Benjamin L
The authors' affiliations are listed in the Appendix.
N Engl J Med. 2014 Dec 25;371(26):2488-98. doi: 10.1056/NEJMoa1408617. Epub 2014 Nov 26.
The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. We hypothesized that such mutations would be detectable in the blood of some persons who are not known to have hematologic disorders.
We analyzed whole-exome sequencing data from DNA in the peripheral-blood cells of 17,182 persons who were unselected for hematologic phenotypes. We looked for somatic mutations by identifying previously characterized single-nucleotide variants and small insertions or deletions in 160 genes that are recurrently mutated in hematologic cancers. The presence of mutations was analyzed for an association with hematologic phenotypes, survival, and cardiovascular events.
Detectable somatic mutations were rare in persons younger than 40 years of age but rose appreciably in frequency with age. Among persons 70 to 79 years of age, 80 to 89 years of age, and 90 to 108 years of age, these clonal mutations were observed in 9.5% (219 of 2300 persons), 11.7% (37 of 317), and 18.4% (19 of 103), respectively. The majority of the variants occurred in three genes: DNMT3A, TET2, and ASXL1. The presence of a somatic mutation was associated with an increase in the risk of hematologic cancer (hazard ratio, 11.1; 95% confidence interval [CI], 3.9 to 32.6), an increase in all-cause mortality (hazard ratio, 1.4; 95% CI, 1.1 to 1.8), and increases in the risks of incident coronary heart disease (hazard ratio, 2.0; 95% CI, 1.2 to 3.4) and ischemic stroke (hazard ratio, 2.6; 95% CI, 1.4 to 4.8).
Age-related clonal hematopoiesis is a common condition that is associated with increases in the risk of hematologic cancer and in all-cause mortality, with the latter possibly due to an increased risk of cardiovascular disease. (Funded by the National Institutes of Health and others.).
血液系统癌症的发病率随年龄增长而增加。这些癌症与特定基因中的反复体细胞突变有关。我们推测,在一些尚无血液系统疾病的人的血液中可检测到此类突变。
我们分析了17182名未根据血液学表型进行选择的人的外周血细胞DNA的全外显子测序数据。我们通过识别先前已鉴定的单核苷酸变异以及血液系统癌症中反复突变的160个基因中的小插入或缺失来寻找体细胞突变。分析突变的存在与血液学表型、生存率和心血管事件之间的关联。
可检测到的体细胞突变在40岁以下的人群中很少见,但随着年龄的增长频率明显上升。在70至79岁、80至89岁和90至108岁的人群中,这些克隆性突变分别在9.5%(2300人中的219人)、11.7%(317人中的37人)和18.4%(103人中的19人)中观察到。大多数变异发生在三个基因中:DNMT3A、TET2和ASXL1。体细胞突变的存在与血液系统癌症风险增加(风险比,11.1;95%置信区间[CI],3.9至32.6)、全因死亡率增加(风险比,1.4;95%CI,1.1至1.8)以及冠心病发病风险增加(风险比,2.0;95%CI,1.2至3.4)和缺血性中风风险增加(风险比,2.6;95%CI,1.4至4.8)相关。
与年龄相关的克隆性造血是一种常见情况,与血液系统癌症风险增加和全因死亡率增加相关,后者可能是由于心血管疾病风险增加所致。(由美国国立卫生研究院等资助。)